Kiniksa Pharmaceuticals's total assets for Q3 2025 were $712.33M, an increase of 7.74% from the previous quarter. KNSA total liabilities were $176.95M for the fiscal quarter, a 6.50% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.